Drug Approval | October 19, 2021
Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
Since its inception, the company has either acquired or taken a majority stake in five companies
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
Deal signed with AOP Orphan for US commercial rights
Complementary business models are the reason for the acquisition
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Subscribe To Our Newsletter & Stay Updated
